Trevi Therapeutics (TRVI) Net Equity Issued and Repurchased (2019)

Trevi Therapeutics (TRVI) posted quarterly Net Equity Issued and Repurchased of $10.0 million for Q1 2019.

Trevi Therapeutics (TRVI) Net Equity Issued and Repurchased (2019) Analysis & Trends

Trevi Therapeutics' Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $10.0 million for Q1 2019.

In Q1 2019, Net Equity Issued and Repurchased changed N/A year-over-year to $10.0 million; the TTM figure through Dec 2019 stood at $10.0 million (changed N/A YoY), while the FY2019 annual figure was $10.0 million, down 5.08% from the prior year.
Net Equity Issued and Repurchased for Q1 2019 stood at $10.0 million.
The five-year high for Net Equity Issued and Repurchased was $10.0 million in Q1 2019, with the low at $10.0 million in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	141.90 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Trevi Therapeutics	2.63 Bn	2.63 Bn	-	-

Download Data

Date	Value
Mar 31, 2019	9.96 Mn
Mar 31, 2019	9.96 Mn